JP6612857B2 - ベンゾイミダゾールアナログおよび関連方法 - Google Patents

ベンゾイミダゾールアナログおよび関連方法 Download PDF

Info

Publication number
JP6612857B2
JP6612857B2 JP2017516254A JP2017516254A JP6612857B2 JP 6612857 B2 JP6612857 B2 JP 6612857B2 JP 2017516254 A JP2017516254 A JP 2017516254A JP 2017516254 A JP2017516254 A JP 2017516254A JP 6612857 B2 JP6612857 B2 JP 6612857B2
Authority
JP
Japan
Prior art keywords
phenyl
benzo
imidazol
butyl
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017516254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519818A (ja
JP2017519818A5 (enExample
Inventor
リ，ホン・ユ
フレット，ブレンダン
サントーロ，マッシモ
カルロマグノ，フランチェスカ
Original Assignee
ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ
ウニベルシタ・フェデリコ・セコンド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ, ウニベルシタ・フェデリコ・セコンド filed Critical ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ
Publication of JP2017519818A publication Critical patent/JP2017519818A/ja
Publication of JP2017519818A5 publication Critical patent/JP2017519818A5/ja
Application granted granted Critical
Publication of JP6612857B2 publication Critical patent/JP6612857B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017516254A 2014-06-03 2015-06-03 ベンゾイミダゾールアナログおよび関連方法 Expired - Fee Related JP6612857B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462007321P 2014-06-03 2014-06-03
US62/007,321 2014-06-03
PCT/US2015/033962 WO2015187818A1 (en) 2014-06-03 2015-06-03 Benzimidazole analogues and related methods

Publications (3)

Publication Number Publication Date
JP2017519818A JP2017519818A (ja) 2017-07-20
JP2017519818A5 JP2017519818A5 (enExample) 2018-07-19
JP6612857B2 true JP6612857B2 (ja) 2019-11-27

Family

ID=54767311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017516254A Expired - Fee Related JP6612857B2 (ja) 2014-06-03 2015-06-03 ベンゾイミダゾールアナログおよび関連方法

Country Status (7)

Country Link
US (1) US9988371B2 (enExample)
EP (1) EP3152194B8 (enExample)
JP (1) JP6612857B2 (enExample)
CN (1) CN107074778B (enExample)
AU (1) AU2015271692B2 (enExample)
ES (1) ES2742192T3 (enExample)
WO (1) WO2015187818A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107176951A (zh) * 2016-03-11 2017-09-19 恩瑞生物医药科技（上海）有限公司 一种脲类化合物、其制备方法及其医药用途
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3856186A4 (en) * 2018-09-28 2022-07-06 Arizona Board of Regents on behalf of the University of Arizona SMALL MOLECULAR DYRK1/CLK INHIBITORS AND USES THEREOF
US12365685B2 (en) 2019-02-18 2025-07-22 Shenzhen Targetrx, Inc. Substituted fused aromatic ring derivative, composition and use thereof
ES2995214T3 (en) * 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment
CN112300106B (zh) * 2020-10-30 2023-03-03 徐州医科大学 一种蛋白激酶抑制剂及制备方法与应用
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用
CN115198256A (zh) * 2022-07-13 2022-10-18 上海天承化学有限公司 一种用于聚酰亚胺薄膜的化学镀铜用还原液及其制备方法和应用
WO2024206989A2 (en) * 2023-03-30 2024-10-03 Bioventures, Llc Flt3 inhibitors and methods of using the same
CN121081464B (zh) * 2025-11-10 2026-02-03 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 小分子抑制剂pz1在治疗kit突变阳性急性髓系白血病中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225054A1 (en) 2002-06-03 2003-12-04 Jingwu Duan Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
WO2005048953A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
GB0507575D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
EP2462135A1 (en) * 2009-08-07 2012-06-13 Janssen R&D Ireland Bis-benzimidazole derivatives as hepatitis c virus inhibitors
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
WO2011150201A2 (en) * 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
WO2012088266A2 (en) * 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
US20140315881A1 (en) * 2011-07-29 2014-10-23 Tempero Pharmaceuticals, Inc. Compounds and methods

Also Published As

Publication number Publication date
EP3152194B1 (en) 2019-05-15
EP3152194B8 (en) 2019-10-09
CN107074778B (zh) 2019-12-13
AU2015271692B2 (en) 2019-05-23
US9988371B2 (en) 2018-06-05
EP3152194A1 (en) 2017-04-12
EP3152194A4 (en) 2018-01-24
JP2017519818A (ja) 2017-07-20
ES2742192T3 (es) 2020-02-13
AU2015271692A1 (en) 2016-12-22
WO2015187818A1 (en) 2015-12-10
US20170101401A1 (en) 2017-04-13
CN107074778A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
CN107074778B (zh) 苯并咪唑类似物和相关方法
JP6425852B1 (ja) エストロゲン受容体調節剤としての６，７−ジヒドロ−５ｈ−ベンゾ［７］アヌレン誘導体
KR102386428B1 (ko) Fgfr 억제제로서 사용되는 헤테로시클릭 화합물
EP3386980B1 (en) Compounds and methods for kinase modulation, and indications therefor
RU2666146C2 (ru) Соединения и способы модулирования киназы и показания к их применению
CN105793260B (zh) 作为用于治疗癌症的raf抑制剂的1‑(5‑叔丁基‑2‑芳基‑吡唑‑3‑基)‑3‑[2‑氟‑4‑[(3‑氧代‑4h‑吡啶并[2，3‑b]吡嗪‑8‑基)氧基]苯基]脲衍生物
US10106538B2 (en) Inhibitors of protein kinases
JP7201586B6 (ja) 神経保護作用、自己免疫性ならびに癌の疾患および病状において有用な１，２－ジチオラン化合物
EA037103B1 (ru) Производные пиридина, обладающие избирательной ингибирующей активностью в отношении ret киназы
US11446287B2 (en) Compounds and methods for EP300 or CBP modulation and indications therefor
JP6512714B2 (ja) 低分子Ｃ−Ｍｙｃ阻害剤
KR20210049862A (ko) 일종의 신형 퀴놀린 유도체 억제제
JP6386585B2 (ja) プロテインキナーゼのインヒビターとしてのフロピリジン
JP2021521178A (ja) Ｐｉ３キナーゼおよびオートファジー経路の調節因子としての三置換アリールおよびヘテロアリール誘導体
CN103402995A (zh) 新型吲哚、吲唑衍生物或其盐
TW201825489A (zh) 五環類化合物、包含其之藥物組合物及其應用
WO2018001084A1 (zh) 热休克蛋白抑制剂及其制备方法和应用
CN113574057A (zh) 杂芳基衍生物及包含其作为活性成分的药物组合物
JP2022551180A (ja) イソクエン酸デヒドロゲナーゼ（ｉｄｈ）阻害剤
HK1242677B (en) Benzimidazole analogues and related methods
HK1242677A1 (en) Benzimidazole analogues and related methods
US20260015328A1 (en) Atm kinase inhibitors
WO2024159088A1 (en) Compounds and methods for yap/tead modulation and indications therefor
BR112021010473A2 (pt) Composto de inibição de dock1 e uso
HK1174038A (en) 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191031

R150 Certificate of patent or registration of utility model

Ref document number: 6612857

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees